Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma ; day:27 ; month:12 ; year:2021 ; extent:22
EMBO molecular medicine / European Molecular Biology Organization ; (27.12.2021) (gesamt 22)
- Urheber
-
Berestjuk, Ilona
Lecacheur, Margaux
Carminati, Alexandrine
Diazzi, Serena
Rovera, Christopher
Prod’homme, Virginie
Ohanna, Mickael
Popovic, Ana
Mallavialle, Aude
Larbret, Frédéric
Pisano, Sabrina
Audebert, Stéphane
Passeron, Thierry
Gaggioli, Cédric
Girard, Christophe A.
Deckert, Marcel
Tartare‐Deckert, Sophie
- DOI
-
10.15252/emmm.201911814
- URN
-
urn:nbn:de:101:1-2021122714123992421545
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Berestjuk, Ilona
- Lecacheur, Margaux
- Carminati, Alexandrine
- Diazzi, Serena
- Rovera, Christopher
- Prod’homme, Virginie
- Ohanna, Mickael
- Popovic, Ana
- Mallavialle, Aude
- Larbret, Frédéric
- Pisano, Sabrina
- Audebert, Stéphane
- Passeron, Thierry
- Gaggioli, Cédric
- Girard, Christophe A.
- Deckert, Marcel
- Tartare‐Deckert, Sophie
Ähnliche Objekte (12)
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling
The immune-related role of BRAF in melanoma
The role of BRAF V600 mutation in melanoma
Clinical significance of BRAF mutations in metastatic melanoma
B-Raf specific antibody responses in melanoma patients
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling
The immune-related role of BRAF in melanoma
The role of BRAF V600 mutation in melanoma
Clinical significance of BRAF mutations in metastatic melanoma
B-Raf specific antibody responses in melanoma patients
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling
The immune-related role of BRAF in melanoma
The role of BRAF V600 mutation in melanoma
Clinical significance of BRAF mutations in metastatic melanoma
B-Raf specific antibody responses in melanoma patients